Dectrekumab/VAK 694Alternative Names: QAX-576/VAK-694; QBX-258; VAK-694/dectrekumab; VAK-694/QAX-576
Latest Information Update: 25 Jan 2016
At a glance
- Originator Novartis
- Class Antiallergics; Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Asthma
Most Recent Events
- 30 Jul 2015 Dectrekumab/VAK 694 is still in phase II trials for Asthma in the USA
- 01 Feb 2012 Phase-II clinical trials in Asthma in USA (IV)